Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
Portfolio Pulse from
Bionano Genomics announced a study from Johns Hopkins showing that their optical genome mapping (OGM) technology outperformed traditional cytogenetic assays in analyzing bone and soft tissue tumors. This supports the extension of OGM's utility beyond hematologic malignancies to solid tumors.
December 23, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bionano Genomics' OGM technology has been shown to outperform traditional cytogenetic assays in a study by Johns Hopkins, potentially expanding its application in cancer diagnostics.
The study from a reputable institution like Johns Hopkins provides strong validation for Bionano's OGM technology, potentially increasing its adoption in cancer diagnostics. This positive development is likely to boost investor confidence and positively impact BNGO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100